Involvement Opportunity for those diagnosed with Alcohol Related Liver Disease (ARLD) and fibrosis (UK)

[BritishLiverTrust1]

Opportunity for those diagnosed with Alcohol Related Liver Disease and fibrosis to take part in the Boehringer Ingelheim 1366-0021 clinical research study

We know that healthy changes can be extremely difficult to make and maintain even when determined. Liver damage caused by alcohol can lead to changes in the body that you may not be aware of. For example, portal hypertension.

Portal hypertension is another way of saying that the pressure in the main blood vessel going to the liver is too high. And although you might not have any outward symptoms, clinically significant portal hypertension (CSPH) is responsible for most complications in people with alcohol-related liver cirrhosis e.g. ascites (collection of fluid in the stomach) and varices (abnormal enlargement of veins which could lead to rupturing and bleeding). Because of this, Boehringer Ingelheim are conducting the 1366-0021 clinical research trial to study the effect of an investigation medication on portal hypertension.

They are looking for people to join the study, who, among other things:

Are between 18 and 75 years old (inclusive)

Have been diagnosed with compensated alcohol-related liver cirrhosis

Have not consumed significant amounts of alcohol in the last 2 months

If you’re interested in taking part please visit: britishlivertrust.org.uk/bo... where details of the sites can be found